150 related articles for article (PubMed ID: 11164145)
1. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.
Shariat SF; Pahlavan S; Baseman AG; Brown RM; Green AE; Wheeler TM; Lerner SP
Urology; 2001 Jan; 57(1):60-5. PubMed ID: 11164145
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
3. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
Karam JA; Lotan Y; Karakiewicz PI; Ashfaq R; Sagalowsky AI; Roehrborn CG; Shariat SF
Lancet Oncol; 2007 Feb; 8(2):128-36. PubMed ID: 17267327
[TBL] [Abstract][Full Text] [Related]
4. The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients.
Serdar A; Turhan C; Soner G; Cem SN; Bayram K; Damla BE; Erbil E
Int Urol Nephrol; 2005; 37(3):485-92. PubMed ID: 16307325
[TBL] [Abstract][Full Text] [Related]
5. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.
Shariat SF; Kim J; Raptidis G; Ayala GE; Lerner SP
Urology; 2003 Jun; 61(6):1140-5. PubMed ID: 12809883
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2014 Feb; 32(1):149-55. PubMed ID: 24616912
[TBL] [Abstract][Full Text] [Related]
8. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection.
Khorrami MH; Hadi M; Gharaati MR; Izadpanahi MH; Javid A; Zargham M
Urol J; 2012; 9(3):581-5. PubMed ID: 22903481
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes].
Cui D; Han BM; Jing YF; Xia SJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):380-3. PubMed ID: 22490896
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.
Shariat SF; Weizer AZ; Green A; Laucirica R; Frolov A; Wheeler TM; Lerner SP
Urology; 2000 Nov; 56(5):735-40. PubMed ID: 11068290
[TBL] [Abstract][Full Text] [Related]
16. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
17. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.
Florianova L; Xu B; Traboulsi S; Elmansi H; Tanguay S; Aprikian A; Kassouf W; Brimo F
World J Surg Oncol; 2015 Nov; 13():317. PubMed ID: 26577765
[TBL] [Abstract][Full Text] [Related]
20. The risk profiles of three clinical types of carcinoma in situ of the bladder.
Meijer RP; van Onna IE; Kok ET; Bosch R
BJU Int; 2011 Sep; 108(6):839-43. PubMed ID: 21166747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
